Answers are grounded in this paper and cite their sources.
Our data highlight that GC-derived TGF-β1 promotes PD-1 independent CD8+ T cell dysfunction. Therefore, restoring CD8+ T cell function by a combinational PD-1 and TGF-β1 blockade might benefit future GC immunotherapy.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: